ObjectiveTo evaluate the effects of cancer on ovarian response in controlled ovarian hyperstimulation (COH).DesignCase controll study.Materials and methods81 cancer patients who underwent controlled ovarian stimulation cycles for fertility preservation were compared to age and date matched controls that underwent COH for in-vitro fertilization (IVF) due to male factor. maximal Estradiol (E2) levels at day of hCG administration, duration of stimulation, total amount of gonadotrophins administrated, number of dominant follicles, number of oocytes retrieved and rate of M2 oocytes were compared.ResultsThe overall number of dominant follicles and the number of oocytes aspirated of the study group and control were comparable (8.8±5.3 vs. 9.7±4.9 and 11.93±8.3 vs. 12.3±7.9 respectively). Total dose of gonadotrophins used and number of stimulation days of the study group (2250 IU (1800-300) and 9.5 (8-11)) were also similar to controls (2100 IU (1700-2900) and 10 (9-13)). Comparison between four subgroups of cancer i.e. breast cancer, soft tissue sarcoma, hematologic malignancies, and gastrointestinal tract cancers, showed no difference in all the above ovarian response indexes. Regression analysis to assess the effect of cancer on ovarian response showed no effect on the main outcome measured.ConclusionCancer does not influence ovarian response in controlled ovarian hyperstimulation for fertility preservation. ObjectiveTo evaluate the effects of cancer on ovarian response in controlled ovarian hyperstimulation (COH). To evaluate the effects of cancer on ovarian response in controlled ovarian hyperstimulation (COH). DesignCase controll study. Case controll study. Materials and methods81 cancer patients who underwent controlled ovarian stimulation cycles for fertility preservation were compared to age and date matched controls that underwent COH for in-vitro fertilization (IVF) due to male factor. maximal Estradiol (E2) levels at day of hCG administration, duration of stimulation, total amount of gonadotrophins administrated, number of dominant follicles, number of oocytes retrieved and rate of M2 oocytes were compared. 81 cancer patients who underwent controlled ovarian stimulation cycles for fertility preservation were compared to age and date matched controls that underwent COH for in-vitro fertilization (IVF) due to male factor. maximal Estradiol (E2) levels at day of hCG administration, duration of stimulation, total amount of gonadotrophins administrated, number of dominant follicles, number of oocytes retrieved and rate of M2 oocytes were compared. ResultsThe overall number of dominant follicles and the number of oocytes aspirated of the study group and control were comparable (8.8±5.3 vs. 9.7±4.9 and 11.93±8.3 vs. 12.3±7.9 respectively). Total dose of gonadotrophins used and number of stimulation days of the study group (2250 IU (1800-300) and 9.5 (8-11)) were also similar to controls (2100 IU (1700-2900) and 10 (9-13)). Comparison between four subgroups of cancer i.e. breast cancer, soft tissue sarcoma, hematologic malignancies, and gastrointestinal tract cancers, showed no difference in all the above ovarian response indexes. Regression analysis to assess the effect of cancer on ovarian response showed no effect on the main outcome measured. The overall number of dominant follicles and the number of oocytes aspirated of the study group and control were comparable (8.8±5.3 vs. 9.7±4.9 and 11.93±8.3 vs. 12.3±7.9 respectively). Total dose of gonadotrophins used and number of stimulation days of the study group (2250 IU (1800-300) and 9.5 (8-11)) were also similar to controls (2100 IU (1700-2900) and 10 (9-13)). Comparison between four subgroups of cancer i.e. breast cancer, soft tissue sarcoma, hematologic malignancies, and gastrointestinal tract cancers, showed no difference in all the above ovarian response indexes. Regression analysis to assess the effect of cancer on ovarian response showed no effect on the main outcome measured. ConclusionCancer does not influence ovarian response in controlled ovarian hyperstimulation for fertility preservation. Cancer does not influence ovarian response in controlled ovarian hyperstimulation for fertility preservation.